Current Clinical Applications and Next Steps for Cardiac Innervation Imaging

Current Cardiology Reports

Volumn 19, Issue 1, 2017, Pages

  Travin, Mark I ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

123I mIBG; Adrenergic imaging; Autonomic nervous system; Heart failure; ICD; Ventricular arrhythmias

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; CADMIUM ZINC TELLURIDE; CARBON META HYDROXYEPHEDRINE C 11; METAL DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; (3 IODOBENZYL)GUANIDINE;

ABLATION THERAPY; ADRENERGIC NERVE; CAMERA; CARDIOVASCULAR RISK; CLINICAL PRACTICE; HEART FAILURE; HEART INNERVATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT VENTRICULAR ASSIST DEVICE; MORTALITY RISK; NONHUMAN; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; ADRENERGIC SYSTEM; ANATOMY AND HISTOLOGY; DIAGNOSTIC IMAGING; HEART; HEART ARRHYTHMIA; INNERVATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRENDS;

3-IODOBENZYLGUANIDINE; ARRHYTHMIAS, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART; HEART FAILURE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; RADIOPHARMACEUTICALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYMPATHETIC NERVOUS SYSTEM;

EID: 85009495375     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-017-0817-2     Document Type: Review

References (100)

1. Bell DR: Control mechanisms in circulatory function. In: Rhoades RA, Bell DR, editors. Medical Physiology: Principles of Clinical Medicine. 4th edition. Philadelphia: Lippincott, Williams & Wilkins, 2013: pp. 317–320.
2. Colucci WS. Pathophysiology of heart failure: Neurohumoral adaptations. http://www.uptodate.com/contents/pathophysiology-of-heart-failure-neurohumoral-adaptations, accessed 4/27/2016; topic last updated August 11, 2015.
3. Travin MI. Application of cardiac neurohormonal imaging to heart failure, transplantation, and diabetes. Curr Cardiovasc Imaging Rep 2015; 8:8 (DOI 10.1007/s12410-015-9323-3.)
4. Francis GS. Neurohormonal control of heart failure. Cleve Clin J Med. 2011;78:S75–9.
5. Lautamäki R, Tipre D, Bengel FM. Cardiac sympathetic neuronal imaging using PET. Eur J Nucl Med Mol Imaging. 2007;34:S74–85.
6. Carrió I. Cardiac neurotransmission imaging. J Nucl Med. 2001;42:1062–76.
7. Zipes DP. Autonomic modulation of cardiac arrhythmias. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. 2nd ed. Philadelphia: WB Saunders Company; 1995. p. 441–2.
8. Kapa S. Somers VK. In: Libby P, Bonow RO, Mann DL, Zipes DP, Braunwald E, editors. Braunwald’s heart disease: a textbook of cardiovascular medicine. 8th ed. Philadelphia: Saunders Elsevier; 2008. p. 2171–83.
9. Flotats A, Carrió I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol. 2004;11:587–602.
10. Verrier RL, Antzelevich C. Autonomic aspects of arrhythmogenesis: the enduring and the new. Curr Opin Cardiol. 2004;19:2–11.
11. Haider N, Baliga RR, Chandrashekhar Y, Narula J. Adrenergic excess, hNET1 down-regulation, and compromised mIBG uptake in heart failure poverty in the presence of plenty. J Am Coll Cardiol Img. 2010;3:71–5.
12. Hattori N, Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart. What have we learned clinically? Eur J Nucl Med. 2000;27:1–6.
13. Raffel DM, Wieland DM. Development of mIBG as a cardiac innervation imaging agent. J Am Coll Cardiol Img. 2010;3:111–6.
14. Bengel FM, Schwaiger M. Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol. 2004;11:603–16.
15. 11C-hydroxyephedrine retention in hibernating myocardium: chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med. 2005;46:1368–74.
16. 18 F-based adrenergic radiotracer
17. 123 I-mIBG that complement and expand on 2010 European Association of Nuclear Medicine Cardiovascular Committee and European Council of Nuclear Cardiology guidelines
18. 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802–12.
19. FDA package insert: http://medlibrary.org/lib/rx/meds/adreview-1/ accessed 5/11/2016.
20. 123 I-mIBG on a CZT solid state camera, including dual isotope imaging at the same sitting, lower patient radiation exposure, and high quality tomographic images, with speculation about potential to enhance risk stratification.
21. Jacobson AF, Senior R, Cerqueira MD. Myocardial iodine 123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (Adreview myocardial imaging for risk evaluation in heart failure). J Am Coll Cardiol. 2010;55:2212–21.
22. Jacobson AF, Lombard J, Banerjee G, Camici PG. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol. 2009;16:113–21.
23. Nakajima K, Okuda K, Yoshimura M, Matsuo S, Wakabayashi H, Imanishi Y, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol. 2014;21:970–8.
24. 99m Tc-tetrofosmin) imaging on a CZT camera is feasible, but that values for HMR are different from those obtained using a standard Anger camera
25. Morozumi T, Kusuoka H, Fukuchi K, Tani A, Uehara T, Matsuda S, et al. Myocardial iodine-123-metaiodobenzylguanidine images and autonomic nerve activity in normal subjects. J Nucl Med. 1997;38:49–52.
26. Tamaki S, Yamada T, Okuyama Y, Morita T, Sanada S, Tsukamoto Y, Masuda M, Okuda K, Iwasaki Y, Yasui T, Hori M, Fukunami M. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol. 2009;53:426–35.
27. Minardo JD, Tuli MM, Mock BH, Weiner RE, Pride HP, Wellmann HN, Zipes DP. Scintigraphic and electrophysiologic evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation. 1988;78:1008–19.
28. Fallavollita JA, Canty JM. Dysinnervated but viable myocardium in ischemic heart disease. J Nucl Cardiol. 2010;17:1107–15.
29. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res. 2004;95:754–63.
30. Boogers MJ, Borleffs CJ, Henneman MM, van Bommel RJ, Van Ramshorst JV, Boersma E, Dibbets-Schneider P, Stokkel MP, van der Wall EE, Schalij MJ, Bax JJ. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 2010;55:2769–77.
31. Clements IP, Garcia EV, Chen J, Folks RD, Butler J, Jacobson AF. Quantitative iodine-123-metaiodobenzylguanidine (MIBG) SPECT imaging in heart failure with left ventricular systolic dysfunction: development and validation of automated procedures in conjunction with technetium-99m tetrofosmin myocardial perfusion SPECT. J Nucl Cardiol. 2016;23:425–35.
32. Travin MI. It’s not all in the numbers. J Nucl Cardiol. 2016;23:436–41. doi:10.1007/s12350-015-0097-4.
33. Schofer J, Spielmann R, Schuchert A, Weber K, Schlüter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1988;12:1252–8.
34. Merlet P, Valette H, Dubois-Randé J, Moyse D, Duboc D, Dove P, Bourguignon MH, Benvenuti C, Duval AM, Agostini D, Loisance D, Castaigne A, Syrota A. Prognostic value of cardiac metaiodobenzylguanidine in patients with heart failure. J Nucl Med. 1992;33:471–7.
35. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147–59.
36. Ketchum ES, Jacobson AF, Caldwell JH, Senior R, Cerqueira MD, Thomas GS, et al. Selective improvement in Seattle heart failure model risk stratification using iodine-123 meta-iodobenzylguanidine imaging. J Nucl Cardiol. 2012;19:1007–16.
37. 123I-MIBG imaging for prediction of mortality and potentially fatal events in heart failure: the ADMIRE-HFX study. J Nucl Med. 2015;56:1011–8. Increased median follow-up time of ADMIRE-HF patients from 17 months to 24 months, and demonstrated that when added to a proportional hazards model containing BNP and LVEF, HMR provided a net reclassification improvement for prediction of mortality and mortality equivalent events
38. Senior R, Friberg L, Travin M, Hudnut F, Chandna H, Agostini D, Ananth K, Miyamoto M, Shah M, Koren M, von Dahl J, Levy W, on behalf of the ADMIRE-HF investigators’ group. Prognostic usefulness of AdreView scintigraphy in identifying heart failure patients at lower risk of death during 5-year follow-up in the ADMIRE-HF study. 1262–238 (ACC 2016 abstract).
39. 123 I-mIBG image results in patients with heart failure, but also showed utility in patients with LVEFs >35%
40. Shah AM, Bourgoun M, Narula J, Jacobson AF, Solomon SD. Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with iodine-123 MIBG in heart failure. J Am Coll Cardiol Img. 2012;5:1139–46.
41. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345:1473–82.
42. 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments—comparison with neurohumoral factors. Circ J. 2002;66:537–43.
43. 123I meta-iodobenzylguanidine heart-to-mediastinum ratio in patients with heart failure: 2- and 5-year risk models. Eur Heart J CV Imaging. 2016; doi:10.1093/ehjci/jev322.
44. Verschure DO, Veltman CE, Manrique A, Somsen GA, Koutelou M, Katsikis A, et al. For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic heart failure? Results of a pooled individual patient data meta-analysis. Eur Heart J Cardiovasc Imaging. 2014;15:996–1003.
45. 99mTc-tetrofosmin single-photon emission computed tomographic images for the prediction of arrhythmic events in patients with ischemic heart failure. J Nucl Cardiol. 2016;23 doi:10.1007/s12350-015-0336-8.
46. Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes 3rd NAM, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2012;60:1297–313.
47. Chen J, Boogers MM, Bax JJ, Soman P, Garcia EV. The use of nuclear imaging for cardiac resynchronization therapy. Curr Cardiol Rep. 2010;12:185–91.
48. 123I-MIBG myocardial scintigraphy. J Nucl Cardiol. 2007;14:852–9.
49. Tanaka H, Tatsumi K, Fujiwara S, Tsuji T, Kaneko A, Ryo K, et al. Effect of left ventricular dyssynchrony on cardiac sympathetic activity in heart failure patients with wide QRS duration. Circ J. 2012;76:382–9.
50. Ambardekar AV, Buttrick PM. Reverse remodeling with left ventricular assist devices: a review of clinical, cellular, and mechanistic effects. Circ Heart Fail. 2011;4:224–33.
51. 123 I-mIBG imaging may help identify patients who are candidates for LVAD explantation.
52. 123 I-mIBG imaging may help identify patients who are candidates for LVAD explantation.
53. Imamura T, Kinugawa K, Nitta D, Kinoshita O, Nawata K, Ono M. Preoperative iodine-123 meta-iodobenzylguanidine imaging is a novel predictor of left ventricular reverse remodeling during treatment with a left ventricular assist device. J Artif Organs. 2016;19:29–36.
54. Barron HV, Lesh MD. Autonomic nervous system and sudden cardiac death. J Am Coll Cardiol. 1996;27:1053–60.
55. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death—executive summary: a report of the American College of Cardiology/American Heart Association task force and the European Society of Cardiology Committee for practice guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death). J Am Coll Cardiol. 2006;48:1064–108.
56. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;128:e240–327.
57. Buxton AE, Lee KL, Hafley GE, Pires LA, Fisher JD, Gold MR, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007;50:1150–7.
58. Myerburg RJ. Implantable cardioverter-defibrillators after myocardial infarction. N Engl J Med. 2008;359:2245–53.
59. Kremers MS, Hammill SC, Berul CI, Koutras C, Curtis JS, Wang Y, Beachy J, Blum Meisnere L, Conyers del M, Reynolds MR, Heidenreich PA, Al-Khatib SM, Pina IL, Blake K, Norine Walsh M, Wilkoff BL, Shalaby A, Masoudi FA, Rumsfeld J. The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm 2013; 10: e59–65
60. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471–80.
61. Lee DS, Krahn AD, Healey JS, et al. Evaluation of early complications related to de novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol. 2010;55:774–82.
62. Al-Khatib SM, Hellkamp A, Curtis J, et al. Non-evidence-based ICD implantations in the United States. JAMA. 2011;305:43–9.
63. Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, et al. I-123 MIBG imaging and heart rate variability analysis to predict the needs for an implantable cardioverter defibrillator. J Nucl Cardiol. 2003;10:121–31.
64. Nagahara D, Nakata T, Hashimoto A, Wakabayashi T, Kyuma M, Noda R, Shimoshige S, Uno K, Tsuchihashi K, Shimamoto K. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med. 2008;49:225–33.
65. 123I–mIBG imaging in patients with systolic dysfunction eligible for implantable cardiac defibrillator implantation. Analysis of data from the prospective ADMIRE-HF study. Circ Cardiovasc Imaging 2015; 8: e003110. DOI: 10.1161/CIRCIMAGING/.114.003110. An interesting study assessing arrhythmic events in ADMIRE-HF who did not have an ICD at study onset, finding that subsequent ICD placement was most cost-effective in patients with an intermediately decreased HMR.
66. 11 C-HED, is effective at identifying patient at increased risk of life threatening arrhythmic events.
67. 123 I-mIBG imaging for patient management in terms of more effectively selecting patients for ICD implantation.
68. 123I-mIBG). J Nucl Cardiol. 2015;22:804–11.
69. Mitrani RD, Klein LS, Miles WM, Hackett FK, Burt RW, Wellman HN, Zipes DP. Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. J Am Coll Cardiol. 1993;22:1344–53.
70. Gill JS, Hunter GJ, Gane J, Ward DE, Camm AJ. Asymmetry of cardiac [123I] meta-iodobenzyl-guanidine scans in patients with ventricular tachycardia and a “Clinically Normal” heart. Br Heart J. 1993;69:6–13.
71. Wichter T, Matheja P, Eckardt L, Kies P, Schäfers K, Schulze-Bahr E, Haverkamp W, Borggrefe M, Schober O, Breithardt G, Schäfers M. Cardiac autonomic dysfunction in Brugada syndrome. Circulation. 2002;105:702–6.
72. Paul M, Wichter T, Kies P, Gerss J, Wollmann C, Rahbar K, et al. Cardiac sympathetic dysfunction in genotyped patients with arrhythmogenic right ventricular cardiomyopathy and risk of recurrent ventricular tachyarrhythmias. J Nucl Med. 2011;52:1559–65.
73. 123I-metaiodobenzylguanidine in chronic Chagas cardiomyopathy. J Nucl Med. 2011;52:504–10.
74. Gadioli LP, Miranda CH, Pintya AO, de Figueiredo AB, Schmidt A, et al. The severity of ventricular arrhythmia correlates with the extent of myocardial sympathetic denervation, but not with myocardial fibrosis extent in Chagas cardiomyopathy: Chagas disease, denervation, and arrhythmias. J Nucl Cardiol. 2016 Jul;5 [Epub ahead of print] doi:10.1007/s12350-016-0556-6.
75. Bax JJ, Kraft O, Buxton AE, Fjeld JG, Parizek P, Agostini D, Knuuti J, Flotats A, Arrighi J, Muxi A, Alibelli MJ, Banerjee G, Jacobson AF. 123 I-MIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: a prospective multicenter pilot study. Circ Cardiovasc Imaging. 2008;1:131–40.
76. Roes SD, Borleffs CJ, van der Geest RJ, Westenberg JJ, Marsan NA, Kaandorp TA, Reiber JH, Zeppenfeld K, Lamb HJ, de Roos A, Schalij MJ, Bax JJ. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmias in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator. Circ Cardiovasc Imaging. 2009;2:183–90.
77. • Zhou Y, Zhou W, Folks RD, Manatunga DN, Jacobson AF, Bax JJ, Garcia EV, Chen J. I-123 mIBG and Tc-99m myocardial SPECT imaging to predict inducibility of ventricular arrhythmia on electrophysiology testing: a retrospective analysis. J Nucl Cardiol. 2014;21:913–20. Novel use of adrenergic imaging to assess arrhythmic potential of mixed tissue located in zones that border infarct or scar
78. 123 I-mIBG -management of patients with intractable ventricular arrhythmias by enhancing detection of successful VT ablation sites.
79. Flotats A, Carrió I. Value of radionuclide studies in cardiac transplantation. Ann Nucl Med. 2006;20:13–21.
80. Di Carli MF, Tobes MC, Mangner T, Levine AB, Muzik O, Chakroborty P, Levine TB. Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J Med. 1997;336:1208–15.
81. Bengel FM, Ueberfuhr P, Schiepel N, Nekolla SG, Reichart B, Schwaiger M. Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med. 2001;345:731–8.
82. • Bravo PE, Lautamäki R, Carter D, Holt DP, Nekolla SG, Dannals RF, et al. Mechanistic insights into sympathetic neuronal regeneration. Multitracer molecular imaging of catecholamine handling after cardiac transplantation. Circ Cardiovasc Imaging 2015; 8:e003507. DOI: 10.1161/CIRCIMAGING. 115.003507. Saw differences in uptake of various PET adrenergic tracers in post-transplant patients. Indicates that the individual tracers depict different aspect of cardiac autonomic pathophysiology, and thus may provide more detailed understanding of pathophysiology in other clinical settings.
83. Henneman MM, Bengel FM, van der Wall EE, Knuuti J, Bax JJ. Cardiac neuronal imaging: application in the evaluation of cardiac disease. J Nucl Cardiol. 2008;3:442–55.
84. Inoue H, Zipes DP. Results of sympathetic denervation in the canine heart: supersensitivity that may be arrhythmogenic. Circulation. 1987;75:877–87.
85. Zipes DP. Influence of myocardial ischemia and infarction on autonomic innervation of heart. Circulation. 1990;82:1095–105.
86. McGhie AI, Corbett JR, Akers MS, Kulkarni P, Sills MN, Kremers M, et al. Regional cardiac adrenergic function using I-123 MIBG SPECT imaging after acute myocardial infarction. Am J Cardiol. 1991;67:236–42.
87. Sasano T, Abraham R, Chang KC, Ashikaga H, Mills KJ, Holt DP, et al. Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction. J Am Coll Cardiol. 2008;51:2266–75.
88. Simões MV, Barthel P, Matsunari I, Nekolla SG, Schömig A, Schwaiger M, et al. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J. 2004;25:551–7.
89. Matsunari I, Schricke U, Bengel FM, Haase H, Barthel P. Schmidt G, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes: circulation. 2000;101:2579–85.
90. D’estanque E, Hedon C, Lattuca B, Bourdon A, Benkiran M, Verd A, et al. Optimization of a simultaneous dual isotope Tl/123IMIBG myocardial SPECT imaging protocol with a CZT camera for trigger zone assessment after myocardial infarction for routine clinical settings: are delayed acquisition and scatter correction necessary? J Nucl Cardiol. 2016; doi:10.1007/s12350-016-0524-1.
91. Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylguanidine imaging in diabetes mellitus assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol. 1995;25:610–8.
92. Hattori N, Tamaki N, Hayashi T, Masuda I, Kudoh T, Tateno M, Tadamura E, Yonekura Y, Nakao K, Konishi J. Regional abnormality of iodine-123-MIBG in diabetic hearts. J Nucl Med. 1996;37:1985–90.
93. Stevens MJ, Raffel DM, Allman KC, Dayanikli F, Ficaro E, Sandford T, Wieland DM, Pfeifer MA, Schwaiger M. Cardiac sympathetic dysinnervation in diabetes. Implications for enhanced cardiovascular risk. Circulation. 1998;98:961–8.
94. Sacre JW, Franjic B, Jellis CL, Jenkins C, Coombes JS, Marwick TH. Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes. JACC Cardiovasc Imaging. 2010;3:1207–15.
95. Nagamachi S, Fujita S, Nishii R, Futami S, Tamura S, Mizuta M, et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol. 2006;13:34–42.
96. Gerson MC, Caldwell JH, Ananthasubramaniam K, Clements IP, Henzlova MJ, Amanullah A, Jacobson AF. Influence of diabetes mellitus on prognostic utility of imaging of myocardial sympathetic innervation in heart failure patients. Circ Cardiovasc Imaging. 2011;4:87–93.
97. 123I meta-iodobenzylguanidine (123I MIBG) scintigraphic study. Diabetes Care. 2013;36:2395–401.
98. 123I]Metaiodobenzylguanidine scintigraphy. Eur J Cancer. 1995;31A:26–31.
99. Carrió I, Estorch M, Berná L, López-Pousa J, Tabernero J, Torres G. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med. 1995;36:2024–49.
100. Bulten BF, Verberne HJ, Bellersen L, Oyen WJG, Sabaté-Llobera A, Mavinkurve-Groothuis AMC, et al. Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients. Cancer Chemother Pharmacol. 2015;76:957–67.